{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:06:09Z","timestamp":1790193969270,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":55,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_844","type":"book-chapter","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:32:28Z","timestamp":1790191948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Delivery Strategies for PROTAC"],"prefix":"10.1007","author":[{"given":"Yijing","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeli","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"844_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118892","volume":"194","author":"M Arenas-Moreira","year":"2026","unstructured":"Arenas-Moreira M, Oca\u00f1a A, Bravo I et al (2026) PROTAC delivery systems: innovative approaches for cancer treatment. Biomed Pharmacother 194:118892","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"844_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM (2022) PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21(3):181\u2013200","journal-title":"Nat Rev Drug Discov"},{"issue":"25","key":"844_CR3","doi-asserted-by":"crossref","first-page":"14155","DOI":"10.1021\/jacs.3c05159","volume":"145","author":"M Chang","year":"2023","unstructured":"Chang M, Gao F, Pontigon D et al (2023) Bioorthogonal PROTAC prodrugs enabled by on-target activation. J Am Chem Soc 145(25):14155\u201314163","journal-title":"J Am Chem Soc"},{"issue":"9","key":"844_CR4","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1021\/acs.jmedchem.4c00152","volume":"67","author":"M Chang","year":"2024","unstructured":"Chang M, Gao F, Gnawali G et al (2024) Selective elimination of senescent cancer cells by Galacto-modified PROTACs. J Med Chem 67(9):7301\u20137311","journal-title":"J Med Chem"},{"issue":"5","key":"844_CR5","volume":"17","author":"G Chen","year":"2025","unstructured":"Chen G (2025) Advances in the oral delivery of protein and peptide drugs. Pharmaceutics 17(5):616","journal-title":"Pharmaceutics"},{"issue":"13","key":"844_CR6","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","volume":"66","author":"C Chen","year":"2023","unstructured":"Chen C, Yang Y, Wang Z et al (2023) Recent advances in pro-PROTAC development to address on-target off-tumor toxicity. J Med Chem 66(13):8428\u20138440","journal-title":"J Med Chem"},{"issue":"15","key":"844_CR7","doi-asserted-by":"crossref","first-page":"10753","DOI":"10.1021\/jacs.4c00826","volume":"146","author":"N Chen","year":"2024","unstructured":"Chen N, Zhang Z, Liu X et al (2024) Sulfatase-induced in situ formulation of antineoplastic supra-PROTACs. J Am Chem Soc 146(15):10753\u201310766","journal-title":"J Am Chem Soc"},{"issue":"95","key":"844_CR8","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1039\/D1CC05715D","volume":"57","author":"W Cheng","year":"2021","unstructured":"Cheng W, Li S, Wen X et al (2021) Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia. Chem Commun 57(95):12852\u201312855","journal-title":"Chem Commun"},{"issue":"10","key":"844_CR9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","volume":"21","author":"B Dale","year":"2021","unstructured":"Dale B, Cheng M, Park KS et al (2021) Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer 21(10):638\u2013654","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"844_CR10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","volume":"17","author":"CV Dang","year":"2017","unstructured":"Dang CV, Reddy EP, Shokat KM et al (2017) Drugging the 'undruggable' cancer targets. Nat Rev Cancer 17(8):502\u2013508","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"844_CR11","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1021\/acs.jmedchem.0c01846","volume":"64","author":"PS Dragovich","year":"2021","unstructured":"Dragovich PS, Pillow TH, Blake RA et al (2021) Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: improvement of in vitro antiproliferation activity and in vivo antitumor efficacy. J Med Chem 64(5):2576\u20132607","journal-title":"J Med Chem"},{"issue":"10","key":"844_CR12","volume":"6","author":"G Fan","year":"2025","unstructured":"Fan G, Chen S, Zhang Q et al (2025) Proteolysis-targeting chimera (PROTAC): current applications and future directions. Med Commun 6(10):e70401","journal-title":"Med Commun"},{"issue":"1","key":"844_CR13","volume":"13","author":"J Gao","year":"2022","unstructured":"Gao J, Hou B, Zhu Q et al (2022) Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy. Nat Commun 13(1):4318","journal-title":"Nat Commun"},{"issue":"10","key":"844_CR14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.scib.2023.04.028","volume":"68","author":"J Gao","year":"2023","unstructured":"Gao J, Yang L, Lei S et al (2023) Stimuli-activatable PROTACs for precise protein degradation and cancer therapy. Sci Bull 68(10):1069\u20131085","journal-title":"Sci Bull"},{"issue":"1","key":"844_CR15","volume":"15","author":"J Gao","year":"2024","unstructured":"Gao J, Jiang X, Lei S et al (2024) A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy. Nat Commun 15(1):6608","journal-title":"Nat Commun"},{"issue":"16","key":"844_CR16","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1021\/acs.jmedchem.5c00468","volume":"68","author":"Y Gao","year":"2025","unstructured":"Gao Y, Ni D, Li Y et al (2025) GLUTs-facilitated targeting BRD4 degradation in breast cancer through carbohydrate-conjugated PROTACs. J Med Chem 68(16):17046\u201317064","journal-title":"J Med Chem"},{"issue":"14","key":"844_CR17","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1021\/acsnano.5c20138","volume":"20","author":"J Gao","year":"2026","unstructured":"Gao J, Lei S, Wang Y et al (2026) Coassembled prodrug nanoparticles mitigating the acquired resistance to protein degradation therapy. ACS Nano 20(14):10982\u201310996","journal-title":"ACS Nano"},{"issue":"43","key":"844_CR18","doi-asserted-by":"crossref","first-page":"23487","DOI":"10.1002\/ange.202107347","volume":"133","author":"S He","year":"2021","unstructured":"He S, Gao F, Ma J et al (2021) Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer. Angew Chem 133(43):23487\u201323493","journal-title":"Angew Chem"},{"key":"844_CR19","volume":"164","author":"Y He","year":"2025","unstructured":"He Y, Liao T, Wang X et al (2025) Application of proteolysis targeting chimeric (PROTAC) technology in protein regulation and drug development. Bioorg Chem 164:108846","journal-title":"Bioorg Chem"},{"issue":"11","key":"844_CR20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrcardio.2017.89","volume":"14","author":"RH Henning","year":"2017","unstructured":"Henning RH, Brundel BJJM (2017) Proteostasis in cardiac health and disease. Nat Rev Cardiol 14(11):637\u2013653","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"844_CR21","doi-asserted-by":"crossref","first-page":"e1907210","DOI":"10.1002\/adma.201907210","volume":"32","author":"B Hou","year":"2020","unstructured":"Hou B, Zhou L, Wang H et al (2020) Engineering stimuli-Activatable Boolean logic prodrug nanoparticles for combination cancer immunotherapy. Adv Mater 32(12):e1907210","journal-title":"Adv Mater"},{"issue":"13","key":"844_CR22","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202411869","volume":"37","author":"X Jiang","year":"2025","unstructured":"Jiang X, Lai Y, Xia W et al (2025) Self-oxygenating PROTAC microneedle for spatiotemporally-confined protein degradation and enhanced glioblastoma therapy. Adv Mater 37(13):e2411869","journal-title":"Adv Mater"},{"issue":"12","key":"844_CR23","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.molcel.2021.05.004","volume":"81","author":"MK Lemberg","year":"2021","unstructured":"Lemberg MK, Strisovsky K (2021) Maintenance of organellar protein homeostasis by ER-associated degradation and related mechanisms. Mol Cell 81(12):2507\u20132519","journal-title":"Mol Cell"},{"issue":"12","key":"844_CR24","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.31635\/ccschem.022.202101529","volume":"4","author":"C Liang","year":"2022","unstructured":"Liang C, Zheng Q, Luo T et al (2022) Enzyme-catalyzed activation of pro-PROTAC for cell-selective protein degradation. CCS Chem 4(12):3809\u20133819","journal-title":"CCS Chem"},{"issue":"8","key":"844_CR25","doi-asserted-by":"crossref","DOI":"10.4028\/b-4W7Te2","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Chen H, Ma L et al (2020) Light-induced control of protein destruction by opto-PROTAC. Sci Adv 6(8):eaay5154","journal-title":"Sci Adv"},{"issue":"19","key":"844_CR26","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1021\/jacs.1c00451","volume":"143","author":"J Liu","year":"2021","unstructured":"Liu J, Chen H, Liu Y et al (2021) Cancer selective target degradation by folate-caged PROTACs. J Am Chem Soc 143(19):7380\u20137387","journal-title":"J Am Chem Soc"},{"issue":"72","key":"844_CR27","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1039\/D2CC03367D","volume":"58","author":"H Liu","year":"2022","unstructured":"Liu H, Ren C, Sun R et al (2022) Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation. Chem Commun 58(72):10072\u201310075","journal-title":"Chem Commun"},{"issue":"6","key":"844_CR28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2215-0366(19)30520-6","volume":"7","author":"S Luza","year":"2020","unstructured":"Luza S, Opazo CM, Bousman CA et al (2020) The ubiquitin proteasome system and schizophrenia. Lancet Psychiatry 7(6):528\u2013537","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"844_CR29","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","volume":"15","author":"M Maneiro","year":"2020","unstructured":"Maneiro M, Forte N, Shchepinova MM et al (2020) Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4. ACS Chem Biol 15(6):1306\u20131312","journal-title":"ACS Chem Biol"},{"issue":"1","key":"844_CR30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-023-00617-4","volume":"18","author":"CD Morrone","year":"2023","unstructured":"Morrone CD, Raghuraman R, Hussaini SA et al (2023) Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer\u2019s disease. Mol Neurodegener 18(1):27","journal-title":"Mol Neurodegener"},{"issue":"5","key":"844_CR31","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/jacs.9b12718","volume":"142","author":"Y Naro","year":"2020","unstructured":"Naro Y, Darrah K, Deiters A (2020) Optical control of small molecule-induced protein degradation. J Am Chem Soc 142(5):2193\u20132197","journal-title":"J Am Chem Soc"},{"key":"844_CR32","doi-asserted-by":"publisher","unstructured":"Pandell N, Househam J, Tartagni M et al (2025) ProMPt: a modular preclinical platform for functional modelling of prostate cancer heterogeneity and therapeutic vulnerabilities. bioRxiv. https:\/\/doi.org\/10.1101\/2025.11.16.688689","DOI":"10.1101\/2025.11.16.688689"},{"issue":"1","key":"844_CR33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41392-025-02405-6","volume":"10","author":"B Park","year":"2025","unstructured":"Park B, Choi J, Lee JH et al (2025) Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy. Signal Transduct Target Ther 10(1):310","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"844_CR34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/acs.biochem.2c00310","volume":"62","author":"RR Paudel","year":"2022","unstructured":"Paudel RR, Lu D, Roy Chowdhury S et al (2022) Targeted protein degradation via lysosomes. Biochemistry 62(3):564\u2013579","journal-title":"Biochemistry"},{"issue":"10","key":"844_CR35","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","volume":"5","author":"P Pfaff","year":"2019","unstructured":"Pfaff P, Samarasinghe KTG, Crews CM et al (2019) Reversible spatiotemporal control of induced protein degradation by Bistable PhotoPROTACs. ACS Cent Sci 5(10):1682\u20131690","journal-title":"ACS Cent Sci"},{"issue":"8","key":"844_CR36","doi-asserted-by":"crossref","first-page":"eaay5064","DOI":"10.1126\/sciadv.aay5064","volume":"6","author":"M Reynders","year":"2020","unstructured":"Reynders M, Matsuura BS, B\u00e9routi M et al (2020) PHOTACs enable optical control of protein degradation. Sci Adv 6(8):eaay5064","journal-title":"Sci Adv"},{"issue":"5","key":"844_CR37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/1568009614666140407112034","volume":"14","author":"A Saneja","year":"2014","unstructured":"Saneja A, Dubey R, Alam N et al (2014) Co-formulation of P-glycoprotein substrate and inhibitor in Nanocarriers: an emerging strategy for cancer chemotherapy. Curr Cancer Drug Targets 14(5):419\u2013433","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"844_CR38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","volume":"17","author":"M Scaranti","year":"2020","unstructured":"Scaranti M, Cojocaru E, Banerjee S et al (2020) Exploiting the folate receptor \u03b1 in oncology. Nat Rev Clin Oncol 17(6):349\u2013359","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"844_CR39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","volume":"18","author":"M Schapira","year":"2019","unstructured":"Schapira M, Calabrese MF, Bullock AN et al (2019) Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov 18(12):949\u2013963","journal-title":"Nat Rev Drug Discov"},{"issue":"40","key":"844_CR40","doi-asserted-by":"crossref","first-page":"36352","DOI":"10.1021\/jacs.5c10240","volume":"147","author":"M Serafini","year":"2025","unstructured":"Serafini M, Twigger SA, Delfas G et al (2025) Indolequinone-based hypoxia-activated proteolysis targeting chimeras selectively degrade BRD4 in hypoxic cancer cells. J Am Chem Soc 147(40):36352\u201336364","journal-title":"J Am Chem Soc"},{"key":"844_CR41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116041","volume":"265","author":"N Setia","year":"2024","unstructured":"Setia N, Almuqdadi HTA, Abid M (2024) Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: from VHL ligands to VHL-based degraders. Eur J Med Chem 265:116041","journal-title":"Eur J Med Chem"},{"issue":"6","key":"844_CR42","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/acs.jmedchem.1c02221","volume":"65","author":"S Shi","year":"2022","unstructured":"Shi S, Du Y, Zou Y et al (2022) Rational design for nitroreductase (NTR)-responsive proteolysis targeting chimeras (PROTACs) selectively targeting tumor tissues. J Med Chem 65(6):5057\u20135071","journal-title":"J Med Chem"},{"issue":"4","key":"844_CR43","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17040501","volume":"17","author":"EW Syahputra","year":"2025","unstructured":"Syahputra EW, Lee H, Cho H et al (2025) PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation. Pharmaceutics 17(4):501","journal-title":"Pharmaceutics"},{"key":"844_CR44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.canlet.2019.01.034","volume":"449","author":"Y Wang","year":"2019","unstructured":"Wang Y, Wang K, Jin Y et al (2019) Endoplasmic reticulum proteostasis control and gastric cancer. Cancer Lett 449:263\u2013271","journal-title":"Cancer Lett"},{"issue":"2","key":"844_CR45","volume":"38","author":"H Wang","year":"2025","unstructured":"Wang H, Zhang T, Lu S et al (2025) A hypoxia-activatable prodrug for targeted combination therapy of hepatoma. Adv Mater 38(2):e12376","journal-title":"Adv Mater"},{"key":"844_CR46","first-page":"235","volume":"19","author":"MR Wilson","year":"2023","unstructured":"Wilson MR, Satapathy S, Vendruscolo M (2023) Extracellular protein homeostasis in neurodegenerative diseases. Nat Rev Neurol 19:235","journal-title":"Nat Rev Neurol"},{"issue":"46","key":"844_CR47","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","volume":"141","author":"G Xue","year":"2019","unstructured":"Xue G, Wang K, Zhou D et al (2019) Light-induced protein degradation with photocaged PROTACs. J Am Chem Soc 141(46):18370\u201318374","journal-title":"J Am Chem Soc"},{"issue":"23","key":"844_CR48","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202002365","volume":"7","author":"B Yang","year":"2020","unstructured":"Yang B, Gao J, Pei Q et al (2020) Engineering prodrug nanomedicine for cancer immunotherapy. Adv Sci 7(23):2002365","journal-title":"Adv Sci"},{"issue":"1","key":"844_CR49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1021\/jacs.2c10177","volume":"145","author":"C Yang","year":"2022","unstructured":"Yang C, Yang Y, Li Y et al (2022) Radiotherapy-triggered proteolysis targeting chimera prodrug activation in tumors. J Am Chem Soc 145(1):385\u2013391","journal-title":"J Am Chem Soc"},{"issue":"12","key":"844_CR50","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.tcb.2023.07.003","volume":"33","author":"J Yang","year":"2023","unstructured":"Yang J, Lee Y, Hwang CS (2023) The ubiquitin-proteasome system links NADPH metabolism to ferroptosis. Trends Cell Biol 33(12):1088\u20131103","journal-title":"Trends Cell Biol"},{"issue":"1","key":"844_CR51","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-025-02444-z","volume":"10","author":"FY Yang","year":"2025","unstructured":"Yang FY, Zhang NY, Yang Y et al (2025) In vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance. Signal Transduct Target Ther 10(1):346","journal-title":"Signal Transduct Target Ther"},{"key":"844_CR52","volume":"382","author":"Y Yu","year":"2025","unstructured":"Yu Y, Hu W, Xu Y et al (2025) Advancements in delivery systems for proteolysis-targeting chimeras (PROTACs): overcoming challenges and expanding biomedical applications. J Control Release 382:113719","journal-title":"J Control Release"},{"issue":"3","key":"844_CR53","volume":"64","author":"J Zhan","year":"2024","unstructured":"Zhan J, Li X, Feng Z et al (2024) MicroRNA-triggered programmable DNA-encoded pre-PROTACs for cell-selective and controlled protein degradation. Angew Chem Int Ed 64(3):e202415323","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"844_CR54","volume":"12","author":"C Zhang","year":"2021","unstructured":"Zhang C, Zeng Z, Cui D et al (2021) Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy. Nat Commun 12(1):2934","journal-title":"Nat Commun"},{"issue":"38","key":"844_CR55","doi-asserted-by":"crossref","first-page":"34672","DOI":"10.1021\/jacs.5c09843","volume":"147","author":"Q Zhu","year":"2025","unstructured":"Zhu Q, Fischer G, Cheng SS et al (2025) Enzyme-activated sugar-coated bifunctional degraders. J Am Chem Soc 147(38):34672\u201334680","journal-title":"J Am Chem Soc"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:32:38Z","timestamp":1790191958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":55,"URL":"https:\/\/doi.org\/10.1007\/164_2026_844","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"24 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}